Point72 Asia (Singapore) Pte. Ltd. Lyell Immunopharma, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $532 Billion
- Q3 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 37,704 shares of LYEL stock, worth $24,130. This represents 0.01% of its overall portfolio holdings.
Number of Shares
37,704Holding current value
$24,130% of portfolio
0.01%Shares
2 transactions
Others Institutions Holding LYEL
# of Institutions
121Shares Held
142MCall Options Held
18.1KPut Options Held
200-
Mwg Management Ltd. Washington, DC20.2MShares$12.9 Million30.81% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$9.66 Million13.96% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$9.66 Million42.56% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$8.64 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$6.45 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $159M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...